In the 2026 market, securing regulatory approval is no longer the final hurdle for medical device manufacturers; it is merely the starting line for a complex Reimbursement Lifecycle. Payers now demand "Economic Evidence" alongside clinical safety data.

The process hinges on three pillars: Coding (obtaining a specific CPT or HCPCS billing code), Coverage (convincing insurers that the device is medically necessary), and Payment (establishing the actual dollar amount reimbursed). A significant trend in 2026 is the expansion of Remote Therapeutic Monitoring (RTM) codes, which incentivize devices that provide real-time data from a patient's home. Manufacturers who fail to integrate a "reimbursement-by-design" strategy early in development often face a "valley of death" where a device is approved by the FDA but remains inaccessible to patients due to a lack of insurance coverage.